Based on these outcomes with improved PFS, better objective responses and more manageable toxicity profiles over systemic chemotherapy, these three TKIs have been approved by Food and Drug Administration of the United States as first-line treatment for metastatic EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.